Balanced news tone
News Sentiment
GALT sentiment intelligence
Galectin Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
49 relevant articles
News tone and price action are not far from neutral.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+2.8% over one week, +47.8% over four weeks, trend active, and materially above fair value.
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
83/100 classification
One-week reaction
2.8%
Price confirming higher
Trend fit
Trend active
47.8% over four weeks
Fair value
58.9%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
10
Neutral
36
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com
Direct company coverage
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock
Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., sold 16,250 shares of common stock for $83,284 on July 14, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he exercised stock options for the same number of shares at a lower price. Following the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 22:42
- Source
- Investing.com
Stock Titan
Direct company coverage
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 each and subsequently sold all 16,250 shares at a weighted average price of $5.1252 on July 14, 2026. This transaction was conducted under a Rule 10b5-1 trad
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 21:42
- Source
- Stock Titan
Investing.com Canada
Direct company coverage
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com
This article reports on a Form 4 filing for Galectin Therapeutics Inc. on July 16, indicating a specific financial disclosure for the company. The stock symbol GALT is mentioned with a performance of -11.24%. The content primarily consists of market data and news headlines from I
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 21:42
- Source
- Investing.com Canada
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
MarketBeat
Direct company coverage
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research
Zacks Research has downgraded Galectin Therapeutics (NASDAQ:GALT) from "hold" to "strong sell." This downgrade comes amidst mixed analyst ratings, with the company currently holding a consensus "Reduce" rating and a target price of $11.00. Galectin Therapeutics recently reported
- Tone
- Negative 30/100
- Event
- Analyst action
- Published
- 15 Jul 2026 10:11
- Source
- MarketBeat
TradingView
Direct company coverage
Price to book forward of Galectin Therapeutics Inc. – NASDAQ:GALT
This article from TradingView provides financial information for Galectin Therapeutics Inc. (NASDAQ: GALT). It specifically highlights the "Price to book forward" metric for the company. The rest of the content consists of navigation, market data sources, and copyright informatio
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 00:11
- Source
- TradingView
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Moomoo
Direct company coverage
$Galectin Therapeutics (GALT.US)$
This page is a community post on moomoo about Galectin Therapeutics (GALT.US). It appears to be a user-generated comment or discussion point, not a formal article or analysis. The content primarily consists of navigation and promotional elements for moomoo itself, with the core m
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 16:40
- Source
- Moomoo
TradingView
Direct company coverage
Enterprise value to revenue forward of Galectin Therapeutics Inc. – NASDAQ:GALT
This article focuses on the "Enterprise value to revenue forward" metric for Galectin Therapeutics Inc. (NASDAQ: GALT). It indicates that financial data for this specific metric is provided by ICE Data Services and FactSet Research Systems Inc. and emphasizes the company's listin
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 16:10
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Galectin Therapeutics Inc. – LSX:A1JV3R
This article provides the "Price to sales forward" for Galectin Therapeutics Inc. (LSX:A1JV3R) on the Lang & Schwarz Exchange. It appears to be a financial data page, indicating that the market is currently closed with no trades. The article is very shallow, providing minimal inf
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 21:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Galectin Therapeutics Inc. – NASDAQ:GALT
This article provides a financial metric, the enterprise value to EBIT forward, for Galectin Therapeutics Inc. (NASDAQ: GALT). It indicates that the NASDAQ market for GALT was closed with no trades at the time of publication. The content appears to be a financial data point from
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 08:42
- Source
- TradingView
Stock Titan
Direct company coverage
If You Invested $1,000 in Galectin Therapeutics Inc (GALT)
This article analyzes the historical performance of investing $1,000 in Galectin Therapeutics Inc (GALT) over different periods, detailing the potential returns and compound annual growth rates. It also provides a company overview, highlighting GALT's focus on developing therapie
- Tone
- Positive 66/100
- Event
- Macro sensitivity
- Published
- 04 Jul 2026 02:09
- Source
- Stock Titan
Investing.com South Africa
Direct company coverage
Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com
This article reports on a Form 4 filing for Galectin Therapeutics Inc. the report is for the June 30th reporting period, and the stock ticker for Galectin Therapeutics is GALT, which experienced a -6.68% change. The article primarily shares this financial filing information witho
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 12:40
- Source
- Investing.com South Africa
Investing.com
Direct company coverage
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock
Jamil Khurram, CMO of Galectin Therapeutics (NASDAQ:GALT), sold $262,083 worth of common stock and acquired $129,481 worth through option exercises between June 26-29, 2026. These transactions were executed under a Rule 10b5-1 plan, leaving him with no direct stock holdings. The
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 01:39
- Source
- Investing.com
Investing.com South Africa
Direct company coverage
Galectin Therapeutics director sells $150,890 in common stock By Investing.com
Harold H. Shlevin, a director at Galectin Therapeutics Inc. (NASDAQ:GALT), sold 30,000 shares of common stock for approximately $150,890, following the acquisition of these shares through stock option exercises. The sales occurred under a Rule 10b5-1 trading plan and coincided wi
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 01:11
- Source
- Investing.com South Africa
Stock Titan
Direct company coverage
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity
Galectin Therapeutics director Harold H. Shlevin exercised stock options for 30,000 shares and simultaneously sold them in open-market transactions on June 26 and June 29, 2026. The sales, executed under a Rule 10b5-1 trading plan, netted approximately $151,000. Following these t
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 01 Jul 2026 00:13
- Source
- Stock Titan
Stock Titan
Direct company coverage
Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale
Jamil Khurram, the Chief Medical Officer of Galectin Therapeutics (GALT), exercised and sold 52,037 shares of common stock in pre-planned transactions on June 26 and 29, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on February 2, 2026, and occurred at p
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 23:23
- Source
- Stock Titan
www.marketscreener.com
Direct company coverage
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark
Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 3000E Growth Benchmark. This inclusion is part of several recent additions to various Russell indices, including the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell 2000, Russell 2000 Value, Rus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 00:13
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark
Galectin Therapeutics Inc. (NasdaqCM:GALT) has been added to the Russell Small Cap Comp Growth Benchmark, as well as several other Russell indices including the Russell 2500 Growth, Russell 2000, and Russell 3000E Index. This news follows recent positive developments for the comp
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 20:41
- Source
- marketscreener.com
Stock Titan
Direct company coverage
Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares
Harold Shlevin, an affiliate of Galectin Therapeutics Inc. (NASDAQ: GALT), has filed a Form 144 indicating a proposed sale of 7,732 shares of common stock. This sale is linked to a stock option exercise from January 23, 2025, with the method noted as "CASH UPON EXERCISE" and a tr
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 29 Jun 2026 19:41
- Source
- Stock Titan
www.marketscreener.com
Direct company coverage
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark
Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 2500 Growth Benchmark as of June 29, 2026. This inclusion reflects the company's growth trajectory and highlights its focus on developing therapies for chronic liver disease and cancer. The biopharmaceutica
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 29 Jun 2026 18:41
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index
Galectin Therapeutics Inc. (NasdaqCM: GALT) has been added to the Russell 3000E Index. The company is a clinical-stage biopharmaceutical organization focused on developing therapies for chronic liver disease and cancer, with its lead drug, belapectin, targeting galectin-3 protein
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 29 Jun 2026 06:40
- Source
- marketscreener.com
Investing.com Nigeria
Direct company coverage
Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com
This article reports on a Form 144 filing for GALECTIN THERAPEUTICS INC on June 26. It notes that the company's stock symbol is GALT and that its price has increased by 17.97%. The brief announcement also includes the Investing.com branding.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 11:10
- Source
- Investing.com Nigeria
Finviz
Direct company coverage
GALT - Galectin Therapeutics Inc Revenue Breakdown
This article provides a detailed financial breakdown for Galectin Therapeutics Inc. (GALT), including key stock performance metrics, insider and institutional ownership, profitability ratios, and short interest data. It shows that GALT's last close was $4.64, with a negative doll
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 00:13
- Source
- Finviz
Stock Titan
Direct company coverage
GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals
A Rule 144 notice for Galectin Therapeutics Inc (NASDAQ: GALT) indicates that Khurram Jamil has reported proposed sales of Common Stock, including recent dispositions of 568 shares on May 26, 2026, and 7,557 shares on June 23, 2026. The filing also details prior stock option exer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 22:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
[144] GALECTIN THERAPEUTICS INC SEC Filing
This article reports on a Form 144 SEC filing by Galectin Therapeutics Inc. (GALT). The filing details a proposed sale of 7,732 shares of common stock by an insider, acquired through a stock option exercise on January 23, 2025. The aggregate market value of the securities to be s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:09
- Source
- Stock Titan
TradingView
Direct company coverage
Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN)
This article provides financial actuals and estimates for Galectin Therapeutics Inc. (FWB:PHPN), detailing its income statement, balance sheet, cash flow, and valuation metrics. It also includes analyst forecasts for the stock price, earnings per share, revenue, and dividend info
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 07:09
- Source
- TradingView
TradingView
Direct company coverage
GALT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Galectin Therapeutics Inc. (GALT) stock, highlighting a consensus analyst price target of $11.00. It covers various financial metrics, stock performance details, and frequently asked questions about GALT, including earnings, revenue, market ca
- Tone
- Positive 72/100
- Event
- Earnings
- Published
- 26 Jun 2026 05:09
- Source
- TradingView
Stock Titan
Direct company coverage
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
Seeking Alpha
Direct company coverage
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Seeking Alpha